JNCCN 360 - BiomarkerNTRK - Ongoing CE Activities

Editors:

Alexander Drilon, MD

Gregory J. Riely, MD, PhD

Advertisement

Advertisement

Ongoing CE Activities

<em>NTRK</em> Fusion in Lung Cancer and the Role of TRK Inhibitors

Caring for Pediatric Patients With <em>NTRK</em> Fusion–Positive Tumors: Strategies to Optimize Your Practice

Emerging and Evolving Biomarkers: <em>NTRK</em>

Expanding Targetable Treatment in Thyroid Cancer: <em>NTRK</em> Fusions

How I Manage Patients With <em>NTRK</em> Fusion–Positive Head and Neck Cancer

NCCN 2021 Virtual Congress: Biomarkers in Solid Tumors

Targeting <em>NTRK</em> Fusions Across Tumor Types

Test Your Knowledge: <em>NTRK</em> Fusions in Head and Neck Cancers

The Latest Advancements in NTRK: Expert Insights from September 2020

Treatment Advances in <em>NTRK</em> Gene–Fusion Positive Sarcoma: What Do You Need to Know?

Sections

NCCN Resources

Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.